QSP - What’s in it for me? Case study examples July 19, 2017 12:00-1:00 PM EDT Register at http://www.rosaandco.com/webinars/2017/damian
Valeriu Damian, Director Systems Modeling and Translational Biology GlaxoSmithKline, King of Prussia, PA Drug discovery efforts, often based on qualitative link between target and disease have resulted in a high rate of late stage clinical failures due to lack of efficacy. Quantitative Systems Pharmacology (QSP) promises to provide the missing quantitative link between the target modulation and clinical outcomes and reduce late stage attrition. Over the last few years QSP has grown as a discipline gaining traction in industry, in academia and in regulatory agencies however there is still a long way to go until all drug discovery and development projects would use QSP models at all stages of development. This talk will look at the QSP modeling from the point of view of project specialists in drug discovery and development and try to address the question in the title: What's in it for me? How can QSP help with my project? Why should I invest in a QSP model? How much can I trust the model? What data do I need to provide? Can I get some insights without having to build and qualify the full QSP model? I would demonstrate with several case studies the QSP modeling benefits and challenges looking both at the decisions that can be influenced by QSP modeling but also at the cost of building and qualifying the model.
